News
GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...
GSK PLC GSK shares dropped 2.45% to £15.12 Friday, on what proved to be an all-around poor trading session for the stock ...
The debate continues over the potential of measurable residual disease to transform research and clinical care in hematology.
GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...
Robert F. Kennedy Jr. faced questions from Congress about his own potential conflicts of interest during a confirmation ...
For the first time, Fortune analyzed the top companies across the continent in partnership with Statista to find the ...
Explore more
GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV ...
3d
MedPage Today on MSNMore Data Back CAR T-Cell Therapy for Lupus, With Promise of Wider AvailabilitySix of the patients, of whom four had non-renal SLE, had follow-up of at least 24 weeks. Of those, five showed dramatic ...
GSK has licensed its shigella vaccine candidate to Bharat Biotech. The Big Pharma, which has vowed to help Bharat with trial ...
2d
Pharmaceutical Technology on MSNBharat Biotech acquires licence for GSK’s Shigella vaccine developmentGSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for the continued development and ...
Nagpur: A blood donation and health check-up camp was organised on Saturday at the MIDC Industries Association (MIA) premises ...
GSK RSV vaccine Arexvy accepted for regulatory review by EMA to expand use in adults 18 years, older
London: GSK plc has announced that the European Medicines Agency (EMA) has accepted the company's regulatory application to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results